专注力抑制
专注力抑制(也被称为注意力分散[1])在医学上被认为是选择性地集中于环境的一个方面而忽略其他事物的能力下降哦。[2][3] 它的最佳特征是强烈的注意力分散感,这会阻止一个人专注于和执行通常相对容易不分心就能完成的基本任务呢。[4] 这种效应通常会与其他并发效应协同作用,如动力抑制、思考减速和镇静喵。[5]
专注力抑制通常伴随着其他并发效应,如镇静、动力抑制和创造力抑制。它最常在中等或严重剂量的抗精神病药、[6]苯二氮卓类物质、大麻类物质[5]和致幻剂影响下被诱发。然而,值得注意的是,在轻微到中等剂量下主要诱发专注力增强的兴奋剂化合物,在其严重剂量下通常也会导致专注力抑制哦。[7]
目录
体验报告
在我们的体验报告索引中,描述了这种效应的轶事报告包括:
- Experience: 1.5g Psilocybe Cubensis - Analysis of body and mind
- Experience:100-350mg - Phenylpiracetam in daily life
- Experience:25mg - A labyrinth of organs and a storybook walk
- Experience:2mg Etizolam - Here be dragons
- Experience:4-HO-MiPT / A care free psychedelic getaway
- Experience:LSD (400ug, Oral) - An afternoon in "a" garden_-An_afternoon_in%22a%22_garden.md)
- Experience:~150mg MDA(oral) - a case of mistaken identity_-_a_case_of_mistaken_identity.md)
另见
外部链接
参考文献
- ↑ "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 820. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms.
- ↑ Lleras, Alejandro; Buetti, Simona; Mordkoff, J. Toby (2013). "When Do the Effects of Distractors Provide a Measure of Distractibility?". 59: 261–315. doi:10.1016/B978-0-12-407187-2.00007-1. ISSN 0079-7421.
- ↑ Ahveninen, Jyrki; Jaaskelainen, Iiro P.; Pekkonen, Eero; Hallberg, Anja; Hietanen, Marja; Naatanen, Risto; Schroger, Erich; Sillanaukee, Pekka (2000). "Increased Distractibility by Task-Irrelevant Sound Changes in Abstinent Alcoholics". Alcoholism: Clinical and Experimental Research. 24 (12): 1850–1854. doi:10.1111/j.1530-0277.2000.tb01989.x. ISSN 0145-6008.
- ↑ McCarthy, Danielle E.; Gloria, Rebecca; Curtin, John J. (2009). "Attention bias in nicotine withdrawal and under stress". Psychology of Addictive Behaviors. 23 (1): 77–90. doi:10.1037/a0014288. ISSN 1939-1501.
- ↑ 5.0 5.1 Kowal, Mikael A.; Hazekamp, Arno; Colzato, Lorenza S.; van Steenbergen, Henk; van der Wee, Nic J. A.; Durieux, Jeffrey; Manai, Meriem; Hommel, Bernhard (2014). "Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users". Psychopharmacology. 232 (6): 1123–1134. doi:10.1007/s00213-014-3749-1. ISSN 0033-3158.
- ↑ Vigen, Cheryl L.P.; Mack, Wendy J.; Keefe, Richard S.E.; Sano, Mary; Sultzer, David L.; Stroup, T. Scott; Dagerman, Karen S.; Hsiao, John K.; Lebowitz, Barry D.; Lyketsos, Constantine G.; Tariot, Pierre N.; Zheng, Ling; Schneider, Lon S. (2011). "Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD". American Journal of Psychiatry. 168 (8): 831–839. doi:10.1176/appi.ajp.2011.08121844. ISSN 0002-953X.
- ↑ Salo, Ruth; Nordahl, Thomas E.; Natsuaki, Yutaka; Leamon, Martin H.; Galloway, Gantt P.; Waters, Christy; Moore, Charles D.; Buonocore, Michael H. (2007). "Attentional Control and Brain Metabolite Levels in Methamphetamine Abusers". Biological Psychiatry. 61 (11): 1272–1280. doi:10.1016/j.biopsych.2006.07.031. ISSN 0006-3223.